{"id":471477,"date":"2021-04-06T07:33:30","date_gmt":"2021-04-06T11:33:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471477"},"modified":"2021-04-06T07:33:30","modified_gmt":"2021-04-06T11:33:30","slug":"olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/","title":{"rendered":"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its Pipeline<\/em>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <em>Longstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chairman of Olema\u2019s Scientific Advisory Board<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>SAN FRANCISCO, April  06, 2021  (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology,\u201d NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced the appointment of Yi Larson to the company\u2019s Board of Directors, and the transition of longstanding Olema director Frank McCormick, Ph.D., F.R.S., D.Sc., to Chair of Olema\u2019s Scientific Advisory Board.<\/p>\n<p>\u201cYi joins Olema at a pivotal time, as we advance the clinical development of our lead program, OP-1250, in breast cancer, and expand our research and development operations,\u201d said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema. \u201cHer demonstrated global operational expertise as Chief Financial Officer of Turning Point Therapeutics, coupled with her extensive capital markets and healthcare banking experience, position her well to provide valuable insights and experience to the Board. We also are fortunate to have Dr. McCormick continue to advise the company as Chair of our Scientific Advisory Board. Given his significant track record in starting and advising numerous successful oncology companies, and his experience on our Board of Directors since 2014, his support and guidance have been immeasurable and have enabled us to move into the clinic with OP-1250.\u201d<\/p>\n<p>\u201cI am impressed with Olema\u2019s science on the estrogen receptor and the potential of its pipeline to improve the lives of women living with breast cancer, and I could not be more excited to join Olema\u2019s Board of Directors as it advances its clinical trials of OP-1250,\u201d said Ms. Larson.<\/p>\n<p>\u201cOn behalf of Olema and the Board of Directors, I welcome Yi to the Board and look forward to working with her as we execute on the company\u2019s mission,\u201d said Ian Clark, Chairman of the Olema Board of Directors. \u201cI am also pleased that Dr. McCormick will continue to advise Olema and our scientific and clinical teams on strategies to advance our pipeline. We thank him for his significant contributions to the company as a director.\u201d<\/p>\n<p>Ms. Larson most recently served as Chief Financial Officer of Turning Point Therapeutics, where she oversaw a period of tremendous growth. Effective May 1, 2021, she will become Chief Financial Officer of LianBio, a private biotech company focusing on precision and innovative therapeutics with operations in the United States and China. Prior to Turning Point, Ms. Larson was a Managing Director of Healthcare Investment Banking at Goldman Sachs, where she successfully executed over 50 transactions, including approximately $70 billion in merger and acquisition activities and $30 billion in financings. She earned an MBA, concentrated in finance, from The Wharton School at the University of Pennsylvania, and a master\u2019s degree in electrical engineering and computer science and a bachelor\u2019s degree in electrical engineering from the Massachusetts Institute of Technology.<\/p>\n<p>\n        <strong>About Olema Oncology<\/strong><br \/>\n        <br \/>Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers. Olema\u2019s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1\/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cgoal,\u201d \u201cestimate,\u201d \u201cpotential\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the development of OP-1250, advancement of Olema\u2019s pipeline and expansion of research and development operations. Because such statements deal with future events and are based on Olema\u2019s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, the risk that Olema\u2019s ongoing or future clinical studies in humans may show that OP-1250 is not a tolerable and effective treatment for breast cancer and other risks and uncertainties affecting Olema, as well as those discussed in the section titled \u201cRisk Factors\u201d in Olema\u2019s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 17, 2021, and future filings and reports that Olema makes from time to time with the United States Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.<\/p>\n<p>Investor Contact:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iwLCcqfVG8Aya2YtpCCBGQM0A2YqypqtYSc6Q5b4bySHF_9aRWo7MJH_CzHCulunsn7-I5ePEChchoZAaDKBWfDMKoPVa_SsciUQTANqgD6M5-B8QIoQzcMUuEsjwbzmIUdEmUL4CSpdDsq2ug4QH2WtE6v20QCklRgVVpY_xHuKyJgVTStocKFQMmL_tPYHSllBpZNKDLU8kavkyLRrOzywIK8Wzc1Pz7WwmZGSxTE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>ir@olema.com<\/u><\/a>\u00a0<\/p>\n<p>Media Contact:<br \/>Sheryl Seapy, Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FyQpo259fNTtYllBznVRcwh3kQIuBrSNCyltJzaZvILP4oU2uZ47JXH4IwVDnBiK2vaU7yXsqKb7iB_wiUNYJV8ytmljmWvLUmW3szcEhcQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">sseapy@realchemistry.com<\/a>\u00a0<br \/>949-903-4750<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/041182c6-8683-4491-93ea-3bc23f18d4e7\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its Pipeline Longstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chairman of Olema\u2019s Scientific Advisory Board SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology,\u201d NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced the appointment of Yi Larson to the company\u2019s Board of Directors, and the transition of longstanding Olema director Frank McCormick, Ph.D., F.R.S., D.Sc., to Chair of Olema\u2019s Scientific Advisory Board. \u201cYi joins Olema at a pivotal time, as &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-471477","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its Pipeline Longstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chairman of Olema\u2019s Scientific Advisory Board SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology,\u201d NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced the appointment of Yi Larson to the company\u2019s Board of Directors, and the transition of longstanding Olema director Frank McCormick, Ph.D., F.R.S., D.Sc., to Chair of Olema\u2019s Scientific Advisory Board. \u201cYi joins Olema at a pivotal time, as &hellip; Continue reading &quot;Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-06T11:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors\",\"datePublished\":\"2021-04-06T11:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/\"},\"wordCount\":898,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/\",\"name\":\"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=\",\"datePublished\":\"2021-04-06T11:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors - Market Newsdesk","og_description":"Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its Pipeline Longstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chairman of Olema\u2019s Scientific Advisory Board SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology,\u201d NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced the appointment of Yi Larson to the company\u2019s Board of Directors, and the transition of longstanding Olema director Frank McCormick, Ph.D., F.R.S., D.Sc., to Chair of Olema\u2019s Scientific Advisory Board. \u201cYi joins Olema at a pivotal time, as &hellip; Continue reading \"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-06T11:33:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors","datePublished":"2021-04-06T11:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/"},"wordCount":898,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/","name":"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=","datePublished":"2021-04-06T11:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTkzMyM0MTA2Nzk1IzIyMDM1MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Olema Oncology Appoints Oncology Biotech Executive\u00a0Yi Larson, MBA, to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=471477"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471477\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=471477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=471477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=471477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}